Immune Monitoring of Prophylactic Effect of Hydroxychloroquine in Healthcare Providers Highly Exposed to COVID-19
NCT04346329 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL
Last updated 2021-05-05
Summary
This is a PILOT STUDY, a Phase III double-blind, randomized, placebo-controlled clinical study in which we assess the clinical effect of the prophylactic administration of hydroxychloroquine vs. placebo to healthcare workers working at our University Hospital (HUN). Participants in each arm (n = 43) will be administered with a unique loading dose of 800 mg of hydroxychloroquine the first day followed by 400 mg/week for 90 days. The population to be studied (uninfected healthcare personnel) will be highly exposed to SARS-CoV-2 infection. An active search should be made for individuals who become infected while participating in the study, hence, once the informed consent form is signed, the molecular test for the diagnosis of SARS-CoV-2 infection by RT-PCR will be carried out every 4 days in order to determine as closely as possible the moment the participant becomes positive. The results of the diagnostic RT-qPCR tests will be confronted with: (i) the results of immune monitoring of at least 30 immunological parameters in leukocytes and in plasma (levels of selected cytokines and chemokines analyzed by automated flow cytometry software and (ii) the daily recording of data for the presence or absence of signs and symptoms associated with SARS-Cov-2 infection. For the recording of immune monitoring 20mL blood samples will be taken at eight-time points throughout the 90 days of the stud.
Conditions
Interventions
- DRUG
-
Hydroxychloroquine
Treated group
- DRUG
-
Placebo oral tablet
Placebo Group
Sponsors & Collaborators
-
Fundación Salud de los Andes
collaborator OTHER -
Universidad Nacional de Colombia
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2020-03-30
- Primary Completion
- 2020-06-30
- Completion
- 2020-10-30
Countries
- Colombia
More Related Trials
-
Factors Associated With Clinical Outcomes in Patients Hospitalized for Covid-19 in GHT-93 Est
NCT04366206 ·Status: UNKNOWN
-
Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients
NCT04324047 ·Status: UNKNOWN
-
COVID-EC Study: Clinical Characteristics of Patients With COVID-19 in Guayaquil, Ecuador
NCT04362969 ·Status: UNKNOWN
-
COVID-19 Hyperinflammation Syndrome (COV-HI): Protocol for a Rapidly Executed Cohort Study
NCT04385069 ·Status: UNKNOWN
-
COVID-19 - Study of the Kinetics of the Immune Response During the Intensive Care Unit Stay in Adult Patients Infected With SARS-CoV-2: Multicentric Non Interventional Study
NCT04392401 ·Status: RECRUITING
-
Understanding COVID-19
NCT04329546 ·Status: COMPLETED
-
An Observational Study of Patients With Coronavirus Disease 2019
NCT04331886 ·Status: COMPLETED
-
Evaluating the Effect of NT-I7, a Long Acting Interleukin-7, to Increase Lymphocyte Counts and Enhance Immune Clearance of SARS-CoV-2 (COVID-19)
NCT04498325 ·Status: WITHDRAWN ·Phase: PHASE1
-
Monitoring the Effectiveness and Safety of COVID-19 Vaccines at National University of Colombia
NCT04887246 ·Status: COMPLETED
-
A COVID-19 Symptom, Exposure and Immune Response Registry
NCT04348942 ·Status: COMPLETED
-
Proxalutamide Treatment for COVID-19 Patients in Intensive Care Unit
NCT04853927 ·Status: WITHDRAWN ·Phase: PHASE3
-
Evaluating the Immune Response for COVID-19
NCT04348422 ·Status: COMPLETED
-
Coronavirus Disease 2019 (COVID-19) Study of Hospitalized Patients in Hong Kong
NCT04325919 ·Status: UNKNOWN
-
Immunophenotyping Assessment in a COVID-19 Cohort
NCT04378777 ·Status: COMPLETED
-
COVID-19 Community Research Partnership
NCT04342884 ·Status: COMPLETED
-
InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection FR BL Cohort
NCT04407689 ·Status: TERMINATED ·Phase: PHASE2
-
Use of a Respiratory Multiplex PCR and Procalcitonin to Reduce Antibiotics Exposure in Patients With Severe Confirmed COVID-19 Pneumonia
NCT04334850 ·Status: COMPLETED ·Phase: NA
-
Pandemic Triage Score in Patients With Known or Suspected Severe Acute Respiratory Syndrome (SARS) CoronaVirus (CoV) 2 Infection
NCT04371471 ·Status: COMPLETED
-
Virological and Immunological Monitoring in Patients (suspected Of/confirmed With) COVID-19
NCT04904692 ·Status: ACTIVE_NOT_RECRUITING
-
InterLeukin-7 (CYT107) to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection UK Cohort
NCT04379076 ·Status: TERMINATED ·Phase: PHASE2
-
HLA-G Immuno-Inhibitor Checkpoint Study in Patients With COVID-19 Infection: Molecular and Cellular Assessment
NCT04613297 ·Status: COMPLETED ·Phase: NA
-
Prophylactic Corticosteroid to Prevent COVID-19 Cytokine Storm
NCT04355247 ·Status: UNKNOWN ·Phase: PHASE2
-
Evaluation of Immune Response in COVID-19 Patients
NCT04438629 ·Status: UNKNOWN
-
Clinical Trial to Evaluate Methylprednisolone Pulses and Tacrolimus in Patients With COVID-19 Lung Injury
NCT04341038 ·Status: UNKNOWN ·Phase: PHASE3
-
Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to Positive
NCT04333589 ·Status: UNKNOWN ·Phase: NA